

The Biology Behind

- The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm.**
□□ *Commentary on Bayliss et al., p. 7029*
Sara Lopez-Tarruella and Rachel Schiff.....6921

Molecular Pathways

- Interleukin-21 Signaling: Functions in Cancer and Autoimmunity.** Ian D. Davis, Kresten Skak, Mark J. Smyth, Paul E.G. Kristjansen, Dennis M. Miller, and Pallavur V. Sivakumar6926

Human Cancer Biology

- Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker?**
Michael Weller, Hilmar Berger, Christian Hartmann, Johannes Schramm, Manfred Westphal, Matthias Simon, Roland Goldbrunner, Dietmar Krex, Joachim P. Steinbach, Christoph B. Ostertag, Markus Loeffler, Torsten Pietsch, and Andreas von Deimling, for The German Glioma Network.....6933

- E2F1 Overexpression Correlates with Thymidylate Synthase and Survivin Gene Expressions and Tumor Proliferation in Non-Small-Cell Lung Cancer.** Cheng-long Huang, Dage Liu, Jun Nakano, Hiroyasu Yokomise, Masaki Ueno, Kyuichi Kadota, and Hiromi Wada6938

- CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer.**
Yukiko Kuniwa, Yoshihiro Miyahara, Helen Y. Wang, Weiyi Peng, Guangyong Peng, Thomas M. Wheeler, Timothy C. Thompson, Lloyd J. Old, and Rong-Fu Wang6947

- Prognostic Role of HuR in Hereditary Breast Cancer.** Mira Heinonen, Rainer Fagerholm, Kirsimari Aaltonen, Outi Kilpivaara, Kristiina Aittomäki, Carl Blomqvist, Päivi Heikkilä, Caj Haglund, Heli Nevanlinna, and Ari Ristimäki6959

- Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia.** Marc R. Mansour, Veronique Duke, Letizia Foroni, Bella Patel, Christopher G. Allen, Phil J. Ancliff, Rosemary E. Gale, and David C. Linch6964

Imaging, Diagnosis, Prognosis

- Stem Cell Marker Nestin and c-Jun NH₂-Terminal Kinases in Tumor and Peritumor Areas of Glioblastoma Multiforme: Possible Prognostic Implications.** Annunziato Mangiola, Gina Lama, Cecilia Giannitelli, Pasquale De Bonis, Carmelo Anile, Libero Lauriola, Giuseppe La Torre, Giovanni Sabatino, Giulio Maira, Meena Jhanwar-Uniyal, and Gigliola Sica6970

- Novel Markers of Subclinical Disease for Ewing Family Tumors from Gene Expression Profiling.** Irene Y. Cheung, Yi Feng, Karen Danis, Neerav Shukla, Paul Meyers, Marc Ladanyi, and Nai-Kong V. Cheung.....6978

- A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy.** Yingye Zheng, Dionyssios Katsaros, Shannon J.C. Shan, Irene Rigault de la Longrais, Mauro Porpiglia, Andreas Scorilas, Nam W. Kim, Robert L. Wolfert, Iris Simon, Lin Li, Ziding Feng, and Eleftherios P. Diamandis.....6984

- Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma.** Rainer Riesenberger, Christoph Weiler, Oliver Spring, Martin Eder, Alexander Buchner, Tanja Popp, Mirna Castro, Robert Kammerer, Osamu Takikawa, Rudolf A. Hatz, Christian G. Stief, Alfons Hofstetter, and Wolfgang Zimmermann.....6993

- A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer.** Karsten Gravdal, Ole J. Halvorsen, Svein A. Haukaas, and Lars A. Akslen7003

Inhibition of the Intrinsic Apoptosis Pathway Downstream of Caspase-9 Activation Causes Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma. Saskia A.G.M. Cillessen, Corine J. Hess, Erik Hooijberg, Kitty C.M. Castricum, Pim Kortman, Fedor Denkers, Wim Vos, Mark A. van de Wiel, Gerrit J. Schuurhuis, Gert J. Ossenkoppele, Chris J.L.M. Meijer, and Joost J. Oudejans	7012
Gain of 1q Is a Potential Univariate Negative Prognostic Marker for Survival in Medulloblastoma. Ken C. Lo, Changxing Ma, Brian N. Bundy, Scott L. Pomeroy, Charles G. Eberhart, and John K. Cowell.....	7022
Reversal of the Estrogen Receptor–Negative Phenotype in Breast Cancer and Restoration of Antiestrogen Response. Jill Bayliss, Amy Hilger, Prakash Vishnu, Kathleen Diehl, and Dorraya El-Ashry.....	7029
Telomere DNA Content Predicts Breast Cancer–Free Survival Interval. Christopher M. Heaphy, Kathy B. Baumgartner, Marco Bisoffi, Richard N. Baumgartner, and Jeffrey K. Griffith	7037
NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model. Jean-Simon Diallo, Abdulhadi Aldejmah, Abdelali Filali Mouhim, Benjamin Péant, Mona Alam Fahmy, Ismaël Hervé Koumakpayi, Kanishka Sircar, Louis R. Bégin, Anne-Marie Mes-Masson, and Fred Saad.....	7044
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer. Daniel C. Danila, Glenn Heller, Gretchen A. Gignac, Rita Gonzalez-Espinoza, Aseem Anand, Erika Tanaka, Hans Lilja, Lawrence Schwartz, Steven Larson, Martin Fleisher, and Howard I. Scher.....	7053
Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials. Claire H. Seedhouse, Martin Grundy, Paul White, Yun Li, Janet Fisher, Darya Yakunina, Anthony V. Moorman, Terence Hoy, Nigel Russell, Alan Burnett, and Monica Pallis.....	7059
High-risk Human Papillomavirus E7 Oncoprotein Detection in Cervical Squamous Cell Carcinoma. Sigrun Ressler, René Scheiden, Kerstin Dreier, Andreas Laich, Elisabeth Müller-Holzner, Haymo Pircher, Dieter Morandell, Ines Stein, Hans-Peter Viertler, Frédéric R. Santer, Andreas Widschwendter, Jos Even, Pidder Jansen-Dürr, Catherine Capesius, and Werner Zwerschke.....	7067

Cancer Therapy: Clinical

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. Jeffrey Haessler, John D. Shaughnessy, Jr., Fenghuang Zhan, John Crowley, Joshua Epstein, Frits van Rhee, Elias Anaissie, Mauricio Pineda-Roman, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, Guido Tricot, and Bart Barlogie.....	7073
BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria. Susan Branford, John F. Seymour, Andrew Grigg, Chris Arthur, Zbigniew Rudzki, Kevin Lynch, and Timothy Hughes.....	7080
Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. Fabienne Thomas, Philippe Rochoix, Adil Benlyazid, Jérôme Sarini, Michel Rives, Jean Louis Lefebvre, Ben C. Allal, Frédéric Courbon, Etienne Chatelut, and Jean-Pierre Delord	7086
Glucocorticoids in the Treatment of Children with Acute Lymphoblastic Leukemia and Hodgkin's Disease: A Pilot Study on the Adverse Psychological Reactions and Possible Associations with Neurobiological, Endocrine, and Genetic Markers. Rosemarie Felder-Puig, Christiane Scherzer, Michaela Baumgartner, Magdalena Ortner, Claudia Aschenbrenner, Christian Bieglmayer, Till Voigtländer, E. Renate Panzer-Grümayer, Wim J.E. Tissing, Jan W. Koper, Karl Steinberger, Christian Nasel, Helmut Gadner, Reinhard Topf, and Michael Dworzak	7093
A Phase 1 Trial Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors. Howard A. Fine, Lyndon Kim, Paul S. Albert, J. Paul Duic, Hilary Ma, Wei Zhang, Tanyifor Tohny, William D. Figg, and Cherly Royce	7101

Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome. Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Peter Hokland, Anna Porwit, and Eva Hellström-Lindberg.....	7107
Phase I Evaluation of CDP791, a PEGylated Di-Fab' Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2. N.C. Ton, G.J.M. Parker, A. Jackson, S. Mullamitha, G.A. Buonaccorsi, C. Roberts, Y. Watson, K. Davies, S. Cheung, L. Hope, F. Power, J. Lawrance, J. Valle, M. Saunders, R. Felix, J.A. Soranson, L. Rolfe, K. Zinkewich-Peotti, and G.C. Jayson	7113
First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer. Arkadiusz Z. Dudek, Carla Yunis, Lester I. Harrison, Sandeep Kumar, Ronald Hawkinson, Sarah Cooley, John P. Vasilakos, Kevin S. Gorski, and Jeffrey S. Miller	7119
Lack of Association of Single-Nucleotide Polymorphisms in <i>Pregnane X Receptor</i>, <i>Hepatic Nuclear Factor 4α</i>, and <i>Constitutive Androstane Receptor</i> with Docetaxel Pharmacokinetics. Lai-San Tham, Nicholas H.G. Holford, Sok-Ying Hor, Theresa Tan, Lingzhi Wang, Rui-Chen Lim, How-Sung Lee, Soo-Chin Lee, and Boon-Cher Goh	7126
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. Monica E. Loghin, Michael D. Prados, Patrick Wen, Larry Junck, Frank Lieberman, Howard Fine, Karen L. Fink, Minesh Metha, John Kuhn, Kathleen Lamborn, Susan M. Chang, Timothy Cloughesy, Lisa M. DeAngelis, Ian H. Robins, Kenneth D. Aldape, and W.K. Alfred Yung.....	7133

Cancer Therapy: Preclinical

Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment. Hajime Orita, Jonathan Coulter, Colleen Lemmon, Ellen Tully, Aravinda Vadlamudi, Susan M. Medghalchi, Francis P. Kuhajda, and Edward Gabrielson.....	7139
Nutritional Modulation of Antitumor Efficacy and Diarrhea Toxicity Related to Irinotecan Chemotherapy in Rats Bearing the Ward Colon Tumor. Hongyu Xue, Michael B. Sawyer, Catherine J. Field, Levinus A. Dieleman, and Vickie E. Baracos	7146
Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme. Chunsheng Liu, Jann N. Sarkaria, Cory A. Petell, Georgia Paraskevaku, Paula J. Zollman, Mark Schroeder, Brett Carlson, Paul A. Decker, Wenting Wu, C. David James, Stephen J. Russell, and Evanthia Galanis.....	7155
Anti-Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts. Raffit Hassan, V. Courtney Broaddus, Shannon Wilson, David J. Liewehr, and Jingli Zhang	7166
CD8⁺ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15-Dependent Mechanism. Taimei Yang, Erika M. Wall, Katy Milne, Patty Theiss, Peter Watson, and Brad H. Nelson	7172
Low-Dose 12-O-Tetradecanoylphorbol-13-Acetate Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells. Xiaoping Zhang, Wenhua Li, and Aria F. Olumi	7181
The Bcl-2/Bcl-X_L Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin. James Witham, Melanie R. Valenti, Alexis K. De-Haven-Brandon, Susanne Vidot, Suzanne A. Eccles, Stan B. Kaye, and Alan Richardson.....	7191
Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer. Marion E. Couch, Robert L. Ferris, Joseph A. Brennan, Wayne M. Koch, Elizabeth M. Jaffee, Michael S. Leibowitz, Gerald T. Nepom, Henry A. Erlich, and David Sidransky	7199

Glutathione S-Transferase T1 and M1: Gene Sequence Variation and Functional Genomics.

Ann M. Moyer, Oreste E. Salavaggione, Scott J. Hebring, Irene Moon, Michelle A.T. Hildebrandt, Bruce W. Eckloff, Daniel J. Schaid, Eric D. Wieben, and Richard M. Weinshilboum7207

Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts.

William C. Zamboni, Sandra Strychor, Erin Joseph, Dustin R. Walsh, Beth A. Zamboni, Robert A. Parise, Margaret E. Tonda, Ning Y. Yu, Charles Engbers, and Julie L. Eiseman.....7217


Correction

Correction: Letter to the Editor on Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2

7224

About the Cover

CDP791 is a PEGylated di-Fab' antibody that binds with high affinity to VEGFR2 and blocks VEGF binding. In a Phase I clinical trial of CDP791, several patients developed cutaneous hemangiomas arising 28 to 106 days after the first drug administration and resolving after cessation. The cover shows immunohistochemical analysis of a hemangioma biopsy indicating that VEGFR2 is nonphosphorylated. Additional immunohistochemistry shows the presence of CDP791 and suggests inhibition of VEGFR2 signaling in these lesions. For further details, please see the article by Ton and associates on page 7113 of this issue.



Clinical Cancer Research

13 (23)

Clin Cancer Res 2007;13:6921-7224.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/13/23>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/13/23>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.